Longevity entrepreneurship: a feature exploring the broader cultural and market conversations sparking renewed interest, experimentation, and debate in aging-focused biotech.
Key Takeaways
- Windfall revenues from GLP-1 weight-loss drugs are being redirected into longevity-focused startups
- Investors and biotech firms are shifting strategy to prioritize aging-related therapeutics and technologies
- Increased capital is accelerating commercialization and increasing mergers